Within the past decade there have been several investigations attempting to define the impact of exogenous and endogenous carbon monoxide exposure on hemostasis. Critically, two bodies of literature have emerged, with carbon monoxide mediated platelet inhibition cited as a cause of *in vitro* human and *in vitro/in vivo* rodent anticoagulation. In contrast, interaction with heme groups associated with fibrinogen, α2-antiplasmin and plasmin by carbon monoxide has resulted in enhanced coagulation and decreased fibrinolysis *in vitro* in human and other species, and *in vivo* in rabbits. Of interest, the ultrastructure of platelet rich plasma thrombi demonstrates an abnormal increase in fine fiber formation and matting that are obtained from humans exposed to carbon monoxide. Further, thrombi obtained from humans and rabbits have very similar ultrastructures, whereas mice and rats have more fine fibers and matting present. In sum, there may be...
species specific differences with regard to hemostatic response to carbon monoxide. Carbon monoxide may be a Janus-faced molecule, with potential to attenuate or exacerbate thrombophilic disease.

**Key Words:** 1) carbon monoxide, 2) platelet, 3) fibrinogen, 4) coagulation, 5) fibrinolysis.

The average, healthy human being produces approximately 400 μl/hour or 10 ml/day of carbon monoxide (CO) [1,2] secondary to catabolism of heme by the ubiquitous heme oxygenase system [3], which includes the inducible isoform, heme oxygenase-1 (HO-1). This results in a normal carboxyhemoglobin (COHb) concentration of less than 1% in healthy individuals [1]. While these data are well accepted, it is rapidly emerging that CO may be a potential therapeutic agent that can be administered a variety of ways. Particularly, increases in either endogenous CO production or environmental CO exposure, may affect hemostasis via modulation of coagulation and fibrinolysis and interestingly this has been noted in several mammalian species [4-76]. There is evidence that excessive CO exposure may result in decreased *in vivo* and *in vitro* hemostasis in humans and rodents [4-8,18-23], potentially by inhibition of platelet aggregation [9-13,15,16,20-23]. However, there is also evidence that increased CO exposure can enhance platelet activation [14,17] and cause enhanced coagulation/decreased fibrinolysis in humans and other mammalian species [28-47,67-76] via modulation of hemostatically active plasma proteins [48-61,63-66]. The purpose of this review is to compare and contrast these seemingly contradictory bodies of literature and suggest a possible mechanistic/structural reconciliation of the apparently divergent hemostatic effects of CO.
Clinical, preclinical and in vitro evidence that CO is an anticoagulant and profibrinolytic agent

If CO diminishes hemostasis, it would be expected that there would be some clinically documented hemorrhagic events in the human literature attributed to CO exposure. Interestingly, hemorrhagic infarction of the brain [4-6], subarachnoid hemorrhage [7], and retinal hemorrhage [8] have been associated with CO poisoning. As a marker of the degree of exposure, circulating COHb concentration is typically used, and in the aforementioned case reports the COHb values varied between 21-35% [4-8]. While these CO associated injuries had a hemorrhagic presentation, the authors posited that the combination of hypoxia-reoxygenation and vasodilatation associated with CO exposure, was the primary mechanism responsible for the acute [7] or subacute [4-6] signs of tissue hemorrhage. Importantly, there were no assessments were made of platelet function or measures of plasmatic coagulation in these patients [4-8].

The mechanism invoked to explain CO associated decreases in coagulation is that platelet aggregation is affected by CO a variety of ways [9-16]. In tobacco smokers [9,10], increases in COHb were not associated with enhancement of platelet aggregation [9] and instead CO exposure was associated with decreased release of adenine diphosphate and serotonin from platelets [10]. Further, CO inhibits calcium entry into human platelets [11], and appears to decrease platelet aggregation by a mechanism independent of an increase of soluble guanylate cyclase [12,16]. It is important to note that these determinations of the effects of CO on platelet aggregation were performed with carbon monoxide releasing molecules (CORMs) [12,16], which is potentially different from inhaled, environmental exposures. These in vitro findings [12,16] were consistent with the observation that
platelet soluble guanylate cyclase activity did not correlate with CO exposure from residential heating of various types [13]. Of interest, an additional, site-directed delivery system of CO described in rodent models includes intravenous administration of CO-loaded, pegylated hemoglobin [77-79]; however, hemostatic effects of this methodology have not been tested. Lastly, in contrast to platelet aggregation studies, determinations of platelet activation by mean platelet volume in healthy volunteers exposed to passive smoking [14], or victims of CO poisoning [17], have demonstrated enhanced activation following exposure to CO. Unfortunately, the COHb values of these poisoned patients were not reported [17]; however, the subjects exposed to cigarette smoke showed COHb value increased by more than 2% [14]. In sum, there is conflict in the in vitro human literature concerning the effects of CO on platelet function, and an in vivo investigation involving a pure exposure to CO (e.g., not CORM or combustion derived CO) and subsequent hemostatic evaluation (e.g., bleeding time), remains to be performed.

While in vivo human investigation of the effect of CO is lacking, there are preclinical rodent models that demonstrate a profibrinolytic and/or antiplatelet effect in vitro and in vivo [18-23]. In hypercholesterolemic mice, upregulation with HO-1 with an adenovirus or exposure to inhaled CO (250 parts per million), decreased thrombus formation following carotid angioplasty, with a decrease in arterial tissue activity of plasminogen activator inhibitor-1, noted [18]. In a rat model of electrical carotid injury and thrombus formation, upregulation of HO-1 activity with hemin administration (an inducer of HO-1 activity) significantly decreased vascular occlusion [19]. In a HO-1 deficient mouse model of allogeneic aortic transplantation, administration of CORMs or wild-type, HO-1 containing platelets prevented graft thrombosis [20]. Similarly, administration of different CORMs
[21,22] or upregulation of HO-1 [23] in rats, decreased intravascular thrombus formation following vascular injury [21,22], increased tail tip amputation bleeding time [21], and improved hepatic reperfusion following ischemia [23]. The proposed mechanism in most of these works involved platelet inhibition [20-23], and unlike in humans [12,16], rats exhibited a soluble guanylate cyclase dependent mechanism by which CO decreased platelet aggregation [21]. Critically, the investigations that evaluated plasmatic coagulation function did not demonstrate any important CO mediated hemostatic changes \textit{in vitro} (e.g., prothrombin time, activated partial thromboplastin time) [21,22]. Of interest, there were variable increases in COHb values in the one study that measured this parameter, with increases in COHb that were either not significant or increased to approximately 6% following exposure to CORMs [22]. In other \textit{in vitro} and \textit{in vivo} investigations involving either mice or rats [24-27], COHb concentrations varied following CORM exposure, with little increase seen with CORMs that release CO quickly (e.g., CORM-3, tricarbonyldichloro(glycinato)ruthenium (II)), contrasted with COHb values between 8% to 17% after exposure to slow releasing CORMs (e.g., CORM-A1, sodium boranocarbonate, \(\text{Na}_2[\text{H}_3\text{BCO}_2]\)). In sum, when exposed to CO at low or high concentrations (based on COHb), platelet function and measures of intravascular thrombus formation were decreased in mice and rats [18-23].

In conclusion, there is anecdotal evidence that CO exposure has been associated with hemorrhagic phenomena in humans, and there is very convincing evidence that increased endogenous/exogenous CO exposure has caused decreased hemostasis in rodent species. Platelet inhibition by CO appears to exist in both human and rodent species, albeit inhibition by different molecular mechanisms. With this in mind, it is
appropriate to consider the literature that describes thrombophilia associated with CO exposure in humans and other species as subsequently presented.

**Clinical evidence that CO is a procoagulant and antifibrinolytic agent**

Thrombophilia associated with CO can be stratified by the degree of exposure and specific thrombotic events. Thus, a consideration of environmental CO exposure and cardiovascular events as well as cerebral vascular events will be presented initially [28-33]. First, looking at the specific subject’s degree of exposure, never smokers in the top quartile of observed circulating COHb (0.91%) were determined to have 3.7-fold the relative risk of cardiovascular events and 2.2-fold the relative risk of death compared to the quartile with the lowest COHb (0.43%) [28]. Increased environmental presence of CO in areas with significant [29] or low [30] air pollution was associated with increased incidence of stroke, and increased workplace exposure to CO [31] in nonsmokers was associated with a 1.97-fold increase in ischemic cardiac death. Even more interesting, among tobacco smokers, the degree of increase in COHb was associated with increased cardiovascular events, stroke and death [32,33]. While supportive of the concept that CO may facilitate thrombophilia in these settings, it must be stressed that none of these settings [28-33] involved exposure to pure CO without exposure to other potential or actual products of combustion (e.g., fine particulate pollution, tobacco smoke).

However, with regard to effects that are predominantly CO mediated, the literature concerning the results of CO poisoning on clinical hemostasis are more substantial. In the case of myocardial infarction, it has been demonstrated that CO poisoning causes myocardial injury in the presence of normal coronary arteries [34-40] and thrombosis of a
coronary arterial stent [41], with COHb values observed as small as 2.6% [40] to as high as 52.2% noted [34], with typical values averaging in the 10-20% range [34-41]. While a likely contributor to myocardial necrosis was hypoxia secondary to decreased oxyhemoglobin and increased COHb, the acute occurrence of coronary artery occlusion/thrombus [38-40] and coronary artery shunt thrombus [41] formation serve as evidence of an acute CO associated thrombophilic event. Even more impressive are the reports of acute intracardiac thrombus in the right atrium [42-44] or left ventricle [45] and pulmonary embolism [46] in patients with the diagnosis of acute CO poisoning; unfortunately, only three of these reports documented circulating COHb, which varied between 16% to 20.2% [43-45]. In addition to these case reports and series [34-45] portraying a procoagulant feature of marked CO exposure, one recent article linked *in vitro* measures of coagulation with clinical CO poisoning in victims with COHb concentrations over 10% [47]. Compared to normal subjects, 48 CO poisoning victims (COHb=21.9±7.9%, mean±SD) had significantly greater plasma concentrations of prothrombin fragment 1+2, plasminogen activator inhibitor-1 and tissue type plasminogen activator with normal fibrinogen concentrations [47]. Spectrophotometric measures of resistance to fibrinolysis also demonstrated that these CO poisoning victims had increased plasmatic resistance to fibrinolysis [47]. Taken as a whole, these aforementioned investigations potentially link CO exposure to thrombophilia [28-46], with increased systemic thrombin generation and hypofibrinolysis being possible mechanisms by which CO were posited to mediate thrombotic events [47].
**In vitro** and preclinical evidence that CO is a procoagulant and antifibrinolytic agent

Late in 2008 it was discovered and subsequently reported that exposure of human plasma to CO released from CORM-2 (tricarbonyldichlororuthenium(II) dimer,

![Figure 1](image_url)

**Figure 1.** Effects of carbon monoxide derived from CORM-2 on plasma coagulation kinetics. Normal plasma was exposed to 0 μM (black hatched trace) or 100 μM CORM-2 (light gray solid trace, equivalent to 70 μM carbon monoxide) before tissue factor activation in a thrombelastograph. Exposure to carbon monoxide increased the velocity of thrombus growth and overall clot strength. Details of how these data are generated have been previously cited [48].
[Ru(CO)$_3$Cl$_2$)$_2$], increased the velocity of thrombus formation and increased final clot strength; this was determined by thrombelastography using either tissue factor or celite activation [48]. The enhancement of coagulation occurred in both normal and Factor XIII deficient plasma [48], implicating either prothrombin or fibrinogen as the protein being acted upon by CO. An example of coagulation kinetic changes secondary to exposure to CORM-2 in normal plasma is displayed (Fig. 1). It was also subsequently determined that CO released from CORM-2 decreased tissue-type plasminogen activator (tPA) mediated fibrinolysis in human plasma, a phenomena that all but disappeared in α$_2$-antiplasmin deficient plasma, implicating α$_2$-antiplasmin and/or plasmin as the molecule(s) modulated by CO [49]. An example of fibrinolytic kinetic changes, secondary to exposure to CORM-2 in normal plasma, is displayed (Fig. 2). Lastly, it was determined that exposure of normal or FXIII deficient plasma to CO decreased thick fiber formation and increased fine fiber formation in thrombi, as determined by transmission electron microscopy [50]. In sum, both coagulation and fibrinolysis in human plasma were affected by CO, resulting in faster growing, stronger clots that were more difficult to lyse, with structural changes in thrombus matrix formation present [48-50].

To determine if CO exposure could be exploited therapeutically to attenuate coagulopathy, several in vitro investigations were conducted wherein various plasma types
Figure 2. Effects of carbon monoxide derived from CORM-2 on plasma fibrinolytic kinetics. Normal plasma was exposed to 0 μM (black hatched trace) or 100 μM CORM-2 (light gray solid trace, equivalent to 70 μM carbon monoxide) before tissue factor activation and exposure to 100 U/ml of tissue-type plasminogen activator in a thrombelastograph. Exposure to carbon monoxide increased the velocity of clot growth, increased clot strength, delayed the onset of fibrinolysis, and prolonged clot lysis time. Details of how these data are generated have been previously cited [49].

were exposed to CORM-2 [51-57]. Plasma obtained from individuals with hemophilia A or B [51], or following warfarin administration [52], or following heparin or argatroban exposure [53], or during hypothermia [54], or following hemodilution with either crystalloid or colloidal solutions [55], or following cardiopulmonary bypass [56], or following protamine
exposure always demonstrated increased velocity of clot formation and strength. And when tested, CORM-2 attenuated tPA mediated fibrinolysis under the aforementioned conditions [52-55,57]. In sum, it appeared that CO could potentially attenuate coagulopathy caused by multiple etiologies.

In order to further characterize the mechanism by which CO enhanced coagulation, experiments involving isolated exposure of prothrombin [58] or fibrinogen [59] to CORM-2 were performed, with the purified protein function assessed in prothrombin or fibrinogen deficient plasmas, respectively. These works lead to the determination that only fibrinogen was affected by CO [58,59], and additional work utilizing mass spectrometry [60] demonstrated that protease digestion of fibrinogen was modified by exposure to CO. More importantly, it was noted that a heme group(s) was present in the fibrinogen digest samples, and following exposure of human plasma to compounds that either produced a carboxyheme or metheme state, plasma strength was increased or decreased respectively, indicative of heme-based modulation of fibrinogen function [60]. Exploiting this newfound redox chemistry of fibrinogen, an assay was devised to determine the presence of CO bound to fibrinogen, named carboxyhemefibrinogen (COHF), as a modification of thrombelastographic methodology [61]. A comparison of a normal subject sample and a sample from a hypercoagulable individual with COHF formation is depicted (Fig. 3). The heme and iron binding characteristics of purified fibrinogen have also been confirmed recently by Orino [62]. With regard to the effects of CO on fibrinolysis, by using varying fibrinolysins and exposing purified α₂-antiplasmin/plasmin to CO or nitric oxide (NO), it was determined that these two enzymes were involved in the hypofibrinolytic effect
Figure 3. Clot strength based assessment of hypercoagulability and carboxyhemefibrinogen (COHF) formation in a normal subject and a lung cancer patient. Analysis of a normal subject is presented on the left side of this figure, and data from a pathologically hypercoagulable lung cancer patient in a recent study [76] is presented on the right side of the figure. The dashed horizontal line indicates the 95th percentile for normal clot strength determined from 30 normal subjects; the normal subject’s plasma strength is below the line, whereas the cancer patient’s corresponding value is well above the line (white columns). A carboxyheme state is induced by addition of CORM-2, whereas a metheme state is created by addition of phenylhydroxylamine (PHA). The difference between the two heme states is depicted as a hatched column with corresponding percentage of this difference compared to the sample without additions displayed over the column. The normal difference is 112%; thus, the normal subject is not considered to have carboxyhemefibrinogen (COHF) formation, but the cancer patient is considered to have COHF present. Specific details concerning the conduct of the thrombelastograph-based assay have been previously described [61,71,73-75].
of CO, acting via a heme-like mechanism [63-66]. Specifically, CO exposure enhanced α₂-antiplasmin activity [65,66] and decreased plasmin activity [66], whereas exposing these two enzymes to a metheme state resulted in downregulation of the activity of both enzymes [66]. Plasmin was demonstrated to have associated heme, but this investigation could not definitively identify α₂-antiplasmin associated heme secondary to the inability to digest this heavily glycosylated enzyme [66]. In sum, it appeared that CO modulated key molecules in the coagulation and fibrinolytic pathways and that this is done via heme based mechanisms.

Subsequent investigations that assessed changes in plasma kinetics \textit{in vitro} and \textit{in vivo}, were conducted to determine if CO exposure changed coagulation in various preclinical animal models [67-70]. Of interest, CO enhanced coagulation and attenuated fibrinolysis in rat, rabbit and horse plasma [67-70]. Further, using a sedated rabbit model measuring ear bleeding times, it was determined that intravenous administration of CORM-2 (10 mg/kg) reduced bleeding time to normal values in a model of aspirin/clopidogrel induced platelet inhibition [68]. Similarly, administration of CORM-2 in a similar rabbit model injected with tPA reduced bleeding time several-fold compared to untreated rabbits, with no wound rebleeding noted in CORM-2 treated rabbits [69]. When considering these aforementioned human and animal investigations, it appeared that CO could promote plasmatic hypercoagulation/hypofibrinolysis via heme-based mechanisms.
Preliminary translational investigations linking CO exposure to plasmatic hypercoagulability in the setting of smoking, mechanical circulatory support and cancer

Utilizing the aforementioned, thrombelastographically-based assay of plasmatic hypercoagulability and COHF formation [61], the role of excessive exogenous or endogenous CO exposure was determined in a variety of settings [71-75]. First, twenty healthy smokers without history of thrombotic illness had their plasmatic coagulation analyzed, with the finding that after smoking two cigarettes within a 90 minute period, 45% were hypercoagulable, 45% had COHF formation, and 20% had both conditions [71]. These healthy smoking subjects had a COHb concentration of 5.0±2.7% at the time of the blood collection [71]. Second, a patient with a left ventricular assist device presented with gross hemolysis and partial pump thrombosis; the COHb varied between 3.1-3.8% during clinical care, and both hypercoagulability and COHF formation were detected [72]. Third, it was serendipitously noted that a patient undergoing removal of thyroid cancer had plasmatic hypercoagulability; this patient had a COHb of 2.4% and was found to have COHF formation [73]. Fourth, in an investigation involving eighteen patients with breast cancer, it was determined that 44% had plasmatic hypercoagulability, 50% had COHF formation, 33% had both hypercoagulability and COHF formation, and the average COHb concentration was 2.5±1.3% [73]. Fifth, in a similarly designed investigation of twenty patients with brain tumors, it was determined that 50% had plasmatic hypercoagulability, 60% had COHF formation, 25% had both hypercoagulability and COHF formation, and the average COHb concentration was 1.5±0.3% [75]. Sixth, in an investigation of 19 patients with thoracic tumors, it was determined that 84% had plasmatic hypercoagulability, 44% of
these hypercoagulable patients had COHF formation, and the average COHb concentration was 2.1±0.6% [76]. In all these clinical situations CO exposure was significant, either as a result of combustion [71] or hemolysis/tumor cell HO-1 upregulation [72-76]. Of particular interest, in the case of exposure of blood to prosthetic biomaterials (e.g., prosthetic heart valves, ventricular assist devices, artificial hearts), there is always the need for anticoagulation, low grade hemolysis is present, and circulating COHb concentrations between 2-3% are observed as recently reviewed [80]. Also of interest, when hematin (an HO-1 inducer) has been administered to treat acute porphyria, phlebitis at the injection site has been noted [81], further when hematin in similar doses was administered to healthy volunteers, a picture of intravascular coagulation occurred, with 45% of the subjects suffering thrombophlebitis [82]. Taken as a whole, in patient populations known to be at risk of thrombotic events, both plasmatic hypercoagulability and COHF formation have been identified [71-76], and patients exposed to HO-1 induction also exhibit signs of hypercoagulability [80-82].

Ultrastructural findings supporting a procoagulant role for CO

Investigations of platelet poor plasma (PPP) or platelet rich plasma (PRP) obtained from samples exposed to CORM-2 [50], obtained from smokers [83,84], obtained from patients with type II diabetes mellitus [85], and rheumatoid arthritis [86] all display similar
features that may be secondary to CO exposure compared to normal subject plasma. While it may be clear that CO exposure occurs in the case of CORM-2 or cigarette exposure, it should be noted that plasmatic HO-1 activity and/or COHb concentration is increased in type II diabetes mellitus [87] and rheumatoid arthritis [88,89]. In the case of
CORM-2 exposure, both normal and factor XIII deficient PPP demonstrated a decrease in large fiber and increase in fine fiber formation as documented by transmission electron microscopy [50]. A similar increase in clot matrix density and fine fiber formation was observed in PPP obtained from smokers as determined by scanning electron microscopy (SEM) [83]. Using PRP, Pretorius and colleagues demonstrated by SEM the formation of not just finer fibers, but also sheet-like matting of thrombus ultrastructure in the settings of smoking [84], type II diabetes mellitus [85] and rheumatoid arthritis [86]. Representative SEM figures of normal PRP and the preceding three conditions are represented (Fig. 4), with methods used to generate these images as previously cited [84-86]. Considered together, these investigations involved conditions or disease states wherein increased CO would be expected to be present, resulting in thrombus ultrastructure (e.g., finer or matted fibers) consistent with enhanced clot strength demonstrated *in vitro* [48,51-57,67,68,70-76] or *in vivo* [68,69] following CO exposure.

However, modulation of fibrinogen-bound heme groups by CO may not be the only mechanism at play in the aforementioned pathological states. First, it has been demonstrated by Lipinski and Pretorius that exposure of purified fibrinogen to ferric ions demonstrated to generate hydroxyl ions without a redox reagent present resulted in aggregation of the fibrinogen [90]. Fenton chemistry may play a role in pathological thrombus formation in diabetes mellitus and other diseases with chronic iron overload [91], and exposure to iron results in SEM evidence of thrombus matting similar to that observed in smoking, diabetes mellitus and rheumatoid arthritis [92,93]. Given the findings of Orino [62] that both iron and heme bind to fibrinogen, it is entirely possible that there are scenarios wherein CO is the primary modulator of fibrinogen functional change (e.g.,
smoking) contrasted to situations involving both CO and iron modulating fibrinogen (e.g., hemolysis, engagement of HO-1 and release of CO and free iron). Indeed, while it is easily argued that the structural changes in thrombi associated with smoking are primarily CO associated, in diabetes mellitus it is likely that iron may have a more prominent role. Nevertheless, the SEM images obtain from smokers or subjects with diabetes mellitus are remarkably similar as displayed (Fig. 4). Future investigation will reveal the role played by either Fenton chemistry or carboxyheme states (or both) in the aforementioned pathological states.

A possible species-specific explanation of disparate hemostatic effects of CO

Given the preceding bodies of evidence, there is little question that CO may very well act as either an anticoagulant or procoagulant, depending on the situation and species. Platelets appear to respond to CO in a similar fashion among human and rodent studies [10-12,16,21,22], but plasmatic coagulation also appears to be enhanced in humans, rats and rabbits [48,51-58,67-69]. In an effort to reveal potential sources of specie specific differences, one may consider the differences in thrombus ultrastructure between humans, rabbits, mice and rats [94,95]. Images of PRP thrombi obtained with SEM reveal a remarkable similarity between humans and rabbits, and a marked difference in structure from mice and rats as displayed (Fig. 5.), which was generated using methods mentioned previously [94,95]. Humans and rabbit thrombi have a less dense matrix, composed of thick and thin fibrin polymers, whereas rodent clots have a more woven, matted structure. How these species-specific differences in ultrastructure impact on plasmatic coagulation kinetics and, ultimately, clinical hemostatic response to CO is
Figure 5. Scanning electron microphotographs of platelet rich plasma thrombi obtained from a human, rabbit, mouse and rat. Panel A = human plasma, Panel B = rabbit plasma, Panel C = mouse plasma, Panel D = rat plasma. Human and rabbit thrombus fibrin polymer formation is remarkably similar, whereas both rodent thrombi markedly differ from human and rabbit. Details of how these data are generated have been previously cited [94,95]. White bar = 1 μm.

unknown. However, one may speculate that rodents intrinsically have a more robust plasmatic contribution to clot strength, tipping the hemostatic balance more towards bleeding if their platelets are inhibited by CO exposure. In contrast, perhaps a greater engagement of plasmatic coagulation by CO in humans, rabbits and other species more than compensates for whatever degree of platelet inhibition may occur, favoring thrombophilia.
Figure 6. Molecular targets of CO and effects on coagulation and fibrinolysis. In the presence of increased HO-1 activity or increased exposure to CO from the environment, the indicated interactions occur in vitro and in vivo. CO decreases platelet aggregation via interaction with soluble guanylate cyclase (sGC) in rodents and decreases aggregation in human platelets by a yet unidentified mechanism. CO interacts with heme groups associated with the indicated molecules, enhancing plasmatic coagulation and attenuating fibrinolysis.

Conclusion

Within the last decade there has been a marked intensification of investigation to elucidate the effects of CO on hemostasis. And remarkably, two substantial bodies of evidence have emerged, with CO being either anticoagulant or procoagulant in nature. The main molecular targets of CO and the likely effects of these interactions on
coagulation and fibrinolysis are summarized as displayed (Fig. 6). Major gaps in knowledge remain – how will humans respond hemostatically if administered CO in isolation, with COHb concentrations increased to values observed in sublethal settings? Does the route of administration (e.g., CORM or inhalation) of CO modify its hemostatic effects? Does the effect of CO on hemostasis depend on species, or does it also depend on whether the clinical picture presents a more platelet or plasma protein dependent coagulopathy or thrombophilic state? While a great deal of investigation has been conducted, the aforementioned and likely many other questions must be answered before CO can be touted as a therapeutic agent or thrombophilic pathological agent. Until then, CO remains a Janus-faced molecule, with potential to attenuate or exacerbate thrombophilic disease.

**Conflict of Interest**

The authors do not have any conflicts of interest to report concerning the present manuscript.

**Funding Source**

Funding for this investigation came solely from departmental sources.

**REFERENCES**


